1. Home
  2. RCS vs PROF Comparison

RCS vs PROF Comparison

Compare RCS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Strategic Income Fund Inc.

RCS

PIMCO Strategic Income Fund Inc.

HOLD

Current Price

$5.46

Market Cap

251.8M

Sector

Finance

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.66

Market Cap

243.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCS
PROF
Founded
1994
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Investment Managers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.8M
243.2M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
RCS
PROF
Price
$5.46
$6.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
139.6K
63.5K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
10.12%
N/A
EPS Growth
N/A
25.89
EPS
N/A
0.19
Revenue
N/A
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
N/A
$64.10
P/E Ratio
N/A
$35.74
Revenue Growth
N/A
50.73
52 Week Low
$5.09
$3.92
52 Week High
$8.00
$8.95

Technical Indicators

Market Signals
Indicator
RCS
PROF
Relative Strength Index (RSI) 50.49 46.15
Support Level $5.36 $6.54
Resistance Level $5.68 $7.07
Average True Range (ATR) 0.13 0.29
MACD 0.01 -0.05
Stochastic Oscillator 46.15 35.67

Price Performance

Historical Comparison
RCS
PROF

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: